
BEST AVAILABLE CUPY



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/PT	0		Complete if Known			
				Application Number	New Application		
INFO	DRMATION	DIS	CLOSURE	Filing Date			
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Dillon, Michael Patrick et al.		
			-	Group Art Unit	unassigned		
	(use as many sh	eets as	necessary)	Examiner Name			
Sheet	1	of	1	Attorney Docket Number	R0130C-REG		

	U.S. PATENT DOCUMENTS										
		U.S. Pa	itent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant					
	Cite No. ¹	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear					
					•						
						,					
· .											
,											

				FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Fo	reign Patent Doc	ument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office 3	Number ⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
	B1	GB	1336 228		Merck & Co., IncUSA	11-07-1973		
	B2	EP	0 887 436	A2	F.Hoffmann- La Roche AG, CH	12-30-1998		

	r	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
	C1	NARDI, D., et al., Hypertensive Activity of 2-(2,3,4,6-tetramethylbenzyl) imidazoline and related compounds," (Research on Durene Derivatives), Farmaco., Ed. Sci. (1979) pp. 789-801, vol. 34(9)	
	C2	LIS, R., et al., "Synthesis and Antiarrhythmic Activity of Novel 3-Alkyl-1-[ω-[4-[(alkylsulfonyl)amino]phenyl]-ω-hydroxyalkyl]-1H-imidazolium Salts and Related Compounds," J. Med. Chem., (1987), pp. 2303-2309, vol. 30.	
		القابية	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 Doc. #120553v1

Please type a plus sign (+) inside this box

Substitute for form 1449A/PTO

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SUPPLEMENTAL **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known					
Application Number	10/421,119				
Filing Date	April 22, 2003				
First Named Inventor	Dillon, Michael Patrick et al.				
Group Art Unit	1626				
Examiner Name	Stockton, Laura				
Attorney Docket Number	R0130C-REG				

		U.S. Patent Docume	nt	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan	
Examiner Initials *	Cite No. ¹	Number Kind Code (if known)	2	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	A1	US 2002/0169193	A1	Pouzet, Pascale, et al.	11-14-2002		
	A2 US 6,602,		B2	Esser, Franz, et al.	08-05-2003		
,	·						

FOREIGN PATENT DOCUMENTS										
5	Cua	Fo	reign Patent D	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines,			
Examiner Initials*	Cite No.1	Office 3	Number⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆		
٠			· .							

No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature		Date Considered	·	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 Doc. #122759v1